Albakri Ahmed Mohammed, Subki Ahmed Hussein, Albeity Abdurahman, Halabi Hussein
Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
J Inflamm Res. 2022 Nov 2;15:6047-6053. doi: 10.2147/JIR.S369477. eCollection 2022.
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been a sudden surge in the incidence of several immune-mediated diseases, including dermatomyositis. The reported cases of COVID-19-related dermatomyositis are heterogeneous in their clinical presentation and implemented therapies.
We report a 23-year-old female patient diagnosed with a 3-year history of dermatomyositis. She has been well-controlled on maintenance therapy. However, 6 weeks after a mild COVID-19 infection, she developed a dermatomyositis flare. She improved only after aggressive treatment with pulse steroids, intravenous immunoglobulin, and rituximab.
Exacerbation of dermatomyositis can be encountered following a COVID-19 infection, even if the infection is mild. Aggressive therapy should be considered in such cases. The prognosis, however, is generally favorable.
自2019年冠状病毒病（COVID-19）大流行开始以来，包括皮肌炎在内的几种免疫介导疾病的发病率突然激增。报告的与COVID-19相关的皮肌炎病例在临床表现和实施的治疗方法上存在异质性。
我们报告一名23岁女性患者，诊断为患有3年皮肌炎病史。她一直通过维持治疗得到良好控制。然而，在轻度COVID-19感染6周后，她出现了皮肌炎发作。仅在接受脉冲类固醇、静脉注射免疫球蛋白和利妥昔单抗的积极治疗后，她才有所改善。
即使感染较轻，COVID-19感染后也可能出现皮肌炎加重。在这种情况下应考虑积极治疗。然而，总体预后良好。
